Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations

References

• Broxmeyer HE. Getting to know JAK. Blood 2011;118:6235–6237.
   PubMed Web of Science ®Google Scholar
• Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004;117:1281–1283.
   PubMed Web of Science ®Google Scholar
• Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008;372:1484–1492.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009;106:9414–9418.
   PubMed Web of Science ®Google Scholar
• Mullighan CG. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice. Clin Cancer Res 2011;17:396–400.
   PubMed Web of Science ®Google Scholar
• Tasian SK, Doral MY, Borowitz MJ, et al. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2- rearranged B-precursor acute lymphoblastic leukemia. Blood 2012;120:833–842.
   PubMed Web of Science ®Google Scholar
• Yoda A, Yoda Y, Chiaretti S, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2010;107:252–257.
   PubMed Web of Science ®Google Scholar
• Kearney L, Gonzalez De Castro D, Yeung J, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009;113:646–648.
   PubMed Web of Science ®Google Scholar
• Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010;116:4874–4884.
   PubMed Web of Science ®Google Scholar
• Roll JD, Reuther GW. CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis. Cancer Res 2010;70:7347–7352.
   PubMed Web of Science ®Google Scholar
• Lee TS, Ma W, Zhang X, et al. Structural effects of clinically observed mutations in JAK2 exons 13–15: comparison with V617F and exon 12 mutations. BMC Struct Biol 2009;9:58–62.
   PubMed Web of Science ®Google Scholar
• Giordanetto F, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng 2002;15:727–737.
   PubMedGoogle Scholar
• Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDock Tools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–2791.
   PubMed Web of Science ®Google Scholar
• Ungureanu D, Wu J, Pekkala T, et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011;18:971–976.
   PubMedGoogle Scholar
• Lindauer K, Loerting T, Liedl KR, et al. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng 2001;14:27–37.
   PubMedGoogle Scholar
• Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem 2005;26:1781–1802.
   PubMed Web of Science ®Google Scholar
• Zhang L, Hermans J. Hydrophilicity of cavities in proteins. Proteins 1996;24:433–438.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Bruccoleri RE, Olafson BD, et al. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983;4:187–217.
   Web of Science ®Google Scholar
• Wu QY, Li F, Guo HY, et al. Amino acid residue E543 in JAK2 C618R is a potential therapeutic target for myeloproliferative disorders caused by JAK2 C618R mutation. Arch Biochem Biophys 2012;528:57–66.
   PubMed Web of Science ®Google Scholar
• Zhao L, Ma Y, Seemann J, et al. A regulating role of the JAK2 FERM domain in hyperactivation of JAK2 (V617F). Biochem J 2010;426: 91–98.
   PubMed Web of Science ®Google Scholar
• Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012;119:2721–2730.
   PubMed Web of Science ®Google Scholar
• Seubert N, Royer Y, Staerk J, et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimmer. Mol Cell 2003;12:1239–1250.
   PubMed Web of Science ®Google Scholar
• Dumoutier L, Van Roost E, Colau D, et al. Human interleukin-10-related T cell-derived inducible factor:molecular cloning and functional characterization as a hepatocyte-stimulating factor. Proc Natl Acad Sci USA 2000;97:10144–10149.
   PubMed Web of Science ®Google Scholar
• Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007;17:8–14.
   PubMed Web of Science ®Google Scholar
• Lafave LM, Levine RL. JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol Sci 2012;33:574–582.
   PubMed Web of Science ®Google Scholar
• Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010;116: 3268–3277.
   PubMed Web of Science ®Google Scholar
• Rui L, Emre NC, Kruhlak MJ, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 2010;18:590–605.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109–3117.
   PubMed Web of Science ®Google Scholar
• Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag 2012;8: 95–103.
   PubMed Web of Science ®Google Scholar
• Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia (ALL). Blood 2012;12:3510–3518.
   Web of Science ®Google Scholar